Aspirin is widely prescribed for the secondary prevention of ischemic stroke and acute coronary syndromes, but some patients do not respond to this therapy. There is evidence that these ...

Baltimore, MD and Durham, NC - More studies linking the effect of antiplatelet drugs on platelet function with clinical outcomes are urgently needed, a new review of the field concludes [1]. The ...

This release is available in Chinese. An analysis of six tests that are used to measure platelet function and help gauge the effectiveness of antiplatelet drugs for patients undergoing a cardiac ...

Randomized trials of platelet function and genetic testing to guide antiplatelet decisions following PCI have produced notoriously mixed results: now, an updated consensus document aims to fill some ...

CHICAGO – Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine ...

In a 2-part series, TCTMD will explore how the GRAVITAS trial is influencing the field of functional platelet testing. Part 1 summarizes the trial and its aftermath, including explanations for the ...

November 15, 2009 (Orlando, Florida) — Results for the first head-to-head comparison of different platelet-function tests suggests that a handful of platelet reactivity assays--used to test the ...

Bleeding because of impaired platelet function is a major side effect of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib. We quantitatively assessed ristocetin-induced platelet aggregation ...

(Ivanhoe Newswire) -- An analysis of six tests used to measure platelet function and gauge the effectiveness of anti-platelet drugs for patients undergoing a cardiac procedure such as a coronary stent ...

Study of the bleeding tendency in uremia in 26 subjects, 10 of whom were bleeding, showed platelet counts and plasma coagulation factors to be normal. There was a significant inverse correlation ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...